BridgeBio Pharma: Genetic Disease Specialist Is Thriving - I'm Upgrading To Buy [Seeking Alpha]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma (BBIO) was upgraded by Royal Bank Of Canada to "moderate buy".
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Strength And Late Stage Pipeline Focus [Yahoo! Finance]
BridgeBio Pharma (BBIO) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $100.00 price target on the stock.